JDNPPA

Check out our conference coverage from the 2026 #Dermatology Essentials for NPs and PAs Meeting with CDNPPA! jdnppa.com/conference-cov…

Managing your vitiligo patients' expectations about treatment is key to ensuring success & building trust in the patient-provider relationship. Leigh Ann Pansch, DCNP & @SeemalRDesaiMD discuss how they counsel patients with #vitiligo about what to expect. jdnppa.com/podcasts/presc…

I have diagnosed & treated countless cases of #urticaria, explaining to patients that the hives are “benign but distressing,” often idiopathic, sometimes autoimmune... But nothing in medical training prepared me for the day I became one of those patients. digitaleditions.walsworth.com/publication/?i…

.@LEOPharmaUS launches “It’s GO time,” the company’s new DTC campaign for #delgocitinib cream (#Anzupgo), the first and only FDA-approved treatment for moderate-to-severe #ChronicHandEczema. Delgocitinib cream is a topical pan-Janus Kinase (JAK) inhibitor. jdnppa.com/leo-launches-n…

US FDA recently gave nod to secukinumab (Cosentyx, @Novartis) for moderate-to-severe #hidradenitissuppurativa in adolescents aged 12+. Douglas DiRuggiero, PA-C, discusses the significance of the approval & what it means for HS patients & #derm providers. jdnppa.com/expert-reactio…

This week, we are showcasing the work of one of our recurring distinguished authors at JDNPPA, Aaron Sookhoo, MMS, PA-C! All links to his recent JDNPPA publications are in the comments.

Treatment of HS often requires a multifaceted, combination approach. This review will help APPs organize their HS options into a “toolbox” in which they can mix and match the appropriate therapies for their patient’s specific situation. #WeekendRead digitaleditions.walsworth.com/publication/?i…

US FDA approves secukinumab (#Cosentyx, @Novartis) for treating pediatric patients 12 years and older with moderate-to-severe #hidradenitissuppurativa (HS). jdnppa.com/us-fda-approve…

[NEW] The first article in this ongoing series focuses on #atopicdermatitis, #tineaversicolor, and #herpessimplex in infants. Read it here: digitaleditions.walsworth.com/publication/?i…

[JUST IN] The @US_FDA launches the FDA Adverse Event Monitoring System (AEMS), a new unified platform for analyzing adverse event reports. jdnppa.com/us-fda-launche…

What are #peptides? Should we eat them? Should we apply them? Sonal Choudhary, MD, talks to Cosmetic #Dermatologist Carolyn Willis, MD, about this hot, but experimental trend in this don’t-miss bonus episode of The Blend! jdnppa.com/podcasts/the-b…

.@CastleBio’s AdvanceAD-Tx test can identify patients with moderate-to-severe #atopicdermatitis who are significantly more likely to achieve greater & faster clinical responses when treated with a JAKi compared to T helper type 2 (Th2)-targeted therapies. jdnppa.com/castles-advanc…

A 55-yo Caucasian male presents with persistent, red, itchy skin patches, present for over a year. He worked as an ultrasound technician at a VA hospital. Past history was unremarkable, he did not smoke/drink alcohol, and he reported a sulfonamide allergy. digitaleditions.walsworth.com/publication/?i…

NEW EPISODE 🎧 What is regenerative medicine? What are exosomes? What about the secretome? Get the answers now as host Sonal Choudhary, MD, grills Carolyn Willis, MD, about all things #regenerative #aesthetics in this episode of the Blend. jdnppa.com/podcasts/the-b…

digitaleditions.walsworth.com/publication/?i… jdnppa.com/diversifying-p… jdnppa.com/wielding-influ…

Your #WeekendRead is brought to you by JDNPPA author, Patricia M. Delgado, DNP! You can find both of her articles included in this issue in the comments below.

[NEW ISSUE] From medical #dermatology to procedural care, NPs and PAs are on the front lines— caring for diverse patient populations, managing long-term diseases, and helping patients navigate increasingly sophisticated treatment options. Dive in: digitaleditions.walsworth.com/publication/?i…